Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review ; volume:42 ; number:03 ; year:2021 ; pages:240-246
Indian journal of medical & paediatric oncology ; 42, Heft 03 (2021), 240-246
- Beteiligte Personen und Organisationen
-
Dabkara, Deepak
- DOI
-
10.1055/s-0041-1732851
- URN
-
urn:nbn:de:101:1-2021110411145750163281
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dabkara, Deepak
Ähnliche Objekte (12)
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer